Case Report: Successful Treatment of Cutaneous Leishmaniasis with Topical Paramomycin in a Child after Treatment Failure with Systemic Fluconazole

Anila Chacko,¹ Marissa Joseph,²,⁴ Timothy Feltis,⁵ and Shaun K. Morris¹,²,³*,⁶

¹Division of Infectious Diseases, Hospital for Sick Children, Toronto, Canada; ²Department of Pediatrics, University of Toronto, Toronto, Canada; ³Centre for Global Child Health, Peter Gilgan Centre for Research and Learning, Hospital for Sick Children Research Institute, Toronto, Canada; ⁴Division of Dermatology, Women's College Hospital, University of Toronto, Toronto, Canada; ⁵Lifelabs Medical Laboratory Services, Toronto, Canada

Abstract. It is challenging to find safe, nonscarring and noninvasive treatment of facial cutaneous leishmaniasis (CL) in children. Herein, we report a child with CL from a region endemic for Leishmania tropica, whose lesion persisted after treatment with oral fluconazole but responded to topical paromomycin. Paromomycin should be considered early for treatment of Old World CL and is a well-tolerated and effective mode of therapy for facial lesions.

CASE REPORT

A 3.5-year-old boy presented to the infectious diseases outpatient clinic at the Hospital for Sick Children, Toronto, with a 4-month history of a progressive, exophytic plaque on his forehead. He was otherwise well with no fever or systemic symptoms. He had emigrated 7 months earlier from Kandahar, Afghanistan, to Ontario, Canada. No other family member had similar lesions at the time. Before presentation to our clinic, he was seen in multiple walk-in clinics where no definitive diagnosis had been made. Various topical therapies including fusidic acid and ketoconazole were used without improvement. Upon referral to a dermatologist, a skin biopsy was performed, which showed a dense diffuse infiltrate in the dermis, numerous histiocytes with abundant pale staining cytoplasm, and innumerable organisms exhibiting paranucleus that had a positive Giemsa stain consistent with leishmaniasis. The child was subsequently referred to our outpatient clinic. Upon further history, it was determined that his father was treated for cutaneous leishmaniasis (CL) when he was 8 years of age with injections, possibly pentavalent antimonial therapy.

At presentation, he had a 2.6 × 1.5 cm pinkish brown infiltrative plaque with central eschar on his forehead (Figure 1). There was no discharge or fluctuation. His physical examination was otherwise unremarkable. His complete blood count, liver function tests, and immunoglobulin levels were normal. In view of the pathological diagnosis of CL (Figure 2), he was started on oral fluconazole 7 mg/kg (100 mg) daily.

At the end of 8 weeks of therapy, there was minimal change in the lesion, and fluconazole therapy was stopped and the child was observed. Within a month of discontinuation of the therapy, the lesion expanded to 3 × 2 cm with surrounding yellow crusting. In view of the nonresponse to fluconazole, he was started on topical paromomycin applied twice daily for 20 days. The treatment response was excellent and the area completely healed by 3 months. Figure 1 shows the residual dyspigmentation, with no evidence of recurrence, at follow-up 1 year later.

FIGURE 1. Lesion at presentation and at follow-up 1 year later.
is effective in 80% of Old World CL lesions, and 400 mg a day is better than 200 mg (81% versus 48% complete healing at 6 weeks).

When it was clear that the lesion was not responding to fluconazole, further treatment of an Old World CL facial lesion which was easy to administer, (81% versus 48% complete healing at 6 weeks). When it was clear that the lesion was not responding to fluconazole, further treatment of an Old World CL facial lesion which was easy to administer, painless, nontraumatic, without major side effects, and with evidence in children was a challenge. Other potential therapeutic options include intralesional stibogluconate, cryotherapy, photodynamic therapy, systemic amphotericin, and sodium stibogluconate. Short-course amphotericin is often effective, however, it requires the administration of an intravenous medication with significant risk for adverse effects including nephrotoxicity.

Paramomycin has recently been shown to be an effective topical treatment of CL in adults. Although we could not find any published trials recommending paramomycin for L. tropica CL in children, literature reports 80% response to paramomycin for Leishmania major CL in studies which included children. Neal and others found that in mouse models, aminosidine (chemically identical to paromomycin) showed high activity against amastigotes of all strains of L. major and L. tropica. A meta-analysis found an advantage of using paramomycin with methylbenzethonium chloride over placebo in Old World CL.

On the basis of this knowledge, we opted to use topical paromomycin for this child. The treatment was well tolerated, with complete resolution and no relapse at 1 year.

CONCLUSION

Our article adds to the growing body of literature that topical paramomycin is an effective and safe mode of therapy for Old World CL in children, especially after treatment failure with fluconazole. Its efficacy in a child with likely L. tropica CL opens up another therapeutic option for children infected with this species. It is especially useful in lesions such as those on the face where other forms of treatment may be invasive and/or have a significant risk profile.

Received November 29, 2015. Accepted for publication July 4, 2016.

Authors' addresses: Anila Chacko, Division of Infectious Diseases, Hospital for Sick Children, Toronto, Canada, E-mail: anilachacko@mcmaster.ca. Marissa Joseph, Department of Pediatrics, University of Toronto, Toronto, Canada, and Division of Dermatology, Women's College Hospital, University of Toronto, Toronto, Canada, E-mail: marissa.joseph@mail.utoronto.ca. Timothy Feltis, Pathology, LifeLabs Medical Laboratory Services, Toronto, Canada, E-mail: tim.feltis@lifelabs.com. Shaun K. Morris, Division of Infectious Diseases, Hospital for Sick Children, Toronto, Canada, and Centre for Global Child Health, Peter Gilgan Centre for Research and Learning, Hospital for Sick Children Research Institute, Toronto, Canada, E-mail: shaun.morris@sickkids.ca.

REFERENCES


